# Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

> **NCT04069897** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **St. Olavs Hospital** · enrollment: 170 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Botulinum toxin type A
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04069897
- **Lead sponsor:** St. Olavs Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-01
- **Primary completion:** 2025-06-13
- **Final completion:** 2026-06
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069897, "Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04069897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*